Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oncology Drug Cost Sharing Would Decline 42% Under Medicare Part D Redesign

Executive Summary

Cost sharing reductions resulting from US Senate drug pricing legislation would vary across categories but the biggest decreases are likely for oncology drugs, antidiabetics and psychotherapeutics, a recent analysis by Manatt Health finds.

You may also be interested in...



Part D Redesign: MedPAC Finalizes Recommendations To Congress But COVID-19 Will Get In The Way

Plan includes new 30% manufacturer discount in the US Medicare Part D catastrophic phase, which manufacturers will oppose as too high. But it also caps beneficiary cost sharing, a long-sought industry goal.

Medicare Could Save More than $80bn With Price Inflation Rebates – CBO Score of Senate Bill

Nearly $70bn in savings over 10 years is expected to result from mandatory price inflation rebates for drugs covered by Medicare Part D.

Medicare’s Final Coverage Decision On Alzheimer’s Drugs: Thoughts From A Former CMS Chief

Mark McClellan discusses whether CMS’s pending final version of the Medicare national coverage determination on Alzheimer’s drugs might change from the draft and whether the decision should be viewed as a precedent for drugs granted accelerated approvals.

Topics

UsernamePublicRestriction

Register

PS142392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel